These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20886611)

  • 1. Exon-skipped dystrophins for treatment of Duchenne muscular dystrophy: mass spectrometry mapping of most exons and cooperative domain designs based on single molecule mechanics.
    Krieger CC; Bhasin N; Tewari M; Brown AE; Safer D; Sweeney HL; Discher DE
    Cytoskeleton (Hoboken); 2010 Dec; 67(12):796-807. PubMed ID: 20886611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?
    Yokota T; Duddy W; Echigoya Y; Kolski H
    Expert Opin Biol Ther; 2012 Sep; 12(9):1141-52. PubMed ID: 22650324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach.
    Wein N; Vulin A; Findlay AR; Gumienny F; Huang N; Wilton SD; Flanigan KM
    J Neuromuscul Dis; 2017; 4(3):199-207. PubMed ID: 28869484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dystrophin's central domain forms a complex filament that becomes disorganized by in-frame deletions.
    Delalande O; Molza AE; Dos Santos Morais R; Chéron A; Pollet É; Raguenes-Nicol C; Tascon C; Giudice E; Guilbaud M; Nicolas A; Bondon A; Leturcq F; Férey N; Baaden M; Perez J; Roblin P; Piétri-Rouxel F; Hubert JF; Czjzek M; Le Rumeur E
    J Biol Chem; 2018 May; 293(18):6637-6646. PubMed ID: 29535188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical and Computational Comparison of Alternative Therapeutic Exon Skip Repairs for Duchenne Muscular Dystrophy.
    Ma KM; Thomas ES; Wereszczynski J; Menhart N
    Biochemistry; 2019 Apr; 58(15):2061-2076. PubMed ID: 30896926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exon skipping and Duchenne muscular dystrophy: hope, hype and how feasible?
    Wilton SD; Fletcher S
    Neurol India; 2008; 56(3):254-62. PubMed ID: 18974551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
    Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
    PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing exon skipping therapies for DMD.
    Yokota T; Duddy W; Partridge T
    Acta Myol; 2007 Dec; 26(3):179-84. PubMed ID: 18646569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method.
    Duchêne B; Iyombe-Engembe JP; Rousseau J; Tremblay JP; Ouellet DL
    Methods Mol Biol; 2018; 1687():267-283. PubMed ID: 29067670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.